Post Profile






Neoadjuvant immunotherapy prior to surgery is safe, feasible in early lung cancer

Neoadjuvant immunotherapy with the PD-1 inhibitor nivolumab is safe and feasible prior to surgery for early lung cancer, researchers report.
read more

share

Related Posts


Immunotherapy drug improves survival for common form of lung cancer

Academics / General Science : ScienceDaily: Science Society

In a head-to-head clinical trial comparing standard chemotherapy with the immunotherapy drug nivolumab, researchers found that people with squamous-non-small cell lung cancer who received nivolumab lived, on average, 3.2 months long...

Immunotherapy Superior to Chemotherapy for Lung Cancer in International Trial

Health : Newswise Medical News

An international team of cancer researchers that included UT Southwestern Medical Center physicians announced "game-changing results" using the immunotherapy drug nivolumab to treat certain lung cancers that failed to respond to fir...

Nivolumab Extends Survival for Patients with Advanced Kidney Cancer Treated Beyond Disease Progression

Health : Newswise Medical News

In a large randomized study, the immunotherapy drug nivolumab, a checkpoint inhibitor, was shown to be a safe and effective therapy for kidney cancer even in patients who continued treatment after their disease progressed.

Immunotherapy Drug Improves Survival for Common Form of Lung Cancer

Health : Newswise Medical News

In a head-to-head clinical trial comparing standard chemotherapy with the immunotherapy drug nivolumab, researchers found that people with squamous-non-small cell lung cancer who received nivolumab lived, on average, 3.2 months long...

Neoadjuvant immunotherapy prior to surgery is safe and feasible in early lung cancer

Health : EurekAlert: Health

(European Society for Medical Oncology) Neoadjuvant immunotherapy with the PD-1 inhibitor nivolumab is safe and feasible prior to surgery for early lung cancer, researchers reported at the ESMO 2016 Congress in Copenhagen.

Comments


Copyright © 2016 Regator, LLC